AP2702A - Methods for improving the pharmacokinetics of HIV integrase inhibitors - Google Patents

Methods for improving the pharmacokinetics of HIV integrase inhibitors

Info

Publication number
AP2702A
AP2702A AP2008004522A AP2008004522A AP2702A AP 2702 A AP2702 A AP 2702A AP 2008004522 A AP2008004522 A AP 2008004522A AP 2008004522 A AP2008004522 A AP 2008004522A AP 2702 A AP2702 A AP 2702A
Authority
AP
ARIPO
Prior art keywords
pharmacokinetics
improving
methods
hiv integrase
integrase inhibitors
Prior art date
Application number
AP2008004522A
Other languages
English (en)
Other versions
AP2008004522A0 (en
Inventor
Brian P Kearney
Atsuyuki Kakee
Isao Kawaguchi
Original Assignee
Gilead Sciences Inc
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Japan Tobacco Inc filed Critical Gilead Sciences Inc
Publication of AP2008004522A0 publication Critical patent/AP2008004522A0/xx
Application granted granted Critical
Publication of AP2702A publication Critical patent/AP2702A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2008004522A 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of HIV integrase inhibitors AP2702A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75503905P 2005-12-30 2005-12-30
US75663106P 2006-01-06 2006-01-06
US76390106P 2006-02-01 2006-02-01
PCT/US2006/049668 WO2007079260A1 (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of hiv integrase inhibitors

Publications (2)

Publication Number Publication Date
AP2008004522A0 AP2008004522A0 (en) 2008-06-30
AP2702A true AP2702A (en) 2013-07-23

Family

ID=38016698

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004522A AP2702A (en) 2005-12-30 2006-12-29 Methods for improving the pharmacokinetics of HIV integrase inhibitors

Country Status (16)

Country Link
US (1) US20070219243A1 (he)
EP (2) EP1976517A1 (he)
JP (1) JP4676536B2 (he)
KR (3) KR101524165B1 (he)
CN (1) CN104069108A (he)
AP (1) AP2702A (he)
AU (1) AU2006332664B2 (he)
BR (1) BRPI0620865A2 (he)
CA (2) CA2847871C (he)
EA (2) EA018544B1 (he)
HR (1) HRP20080313A2 (he)
IL (1) IL192208A (he)
NO (1) NO20083333L (he)
NZ (1) NZ569576A (he)
SG (2) SG170795A1 (he)
WO (1) WO2007079260A1 (he)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
LT2487163T (lt) 2007-02-23 2016-10-25 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
EP2167088A1 (en) * 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
WO2009092002A1 (en) * 2008-01-17 2009-07-23 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
PT3494972T (pt) * 2010-01-27 2024-02-12 Viiv Healthcare Co Combinações de dolutegravir e lamivudina para o tratamento de infeção pelo hiv
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
AU2013361401C1 (en) 2012-12-21 2018-08-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (he) 2013-07-12 2018-07-21
PL3019503T3 (pl) 2013-07-12 2018-01-31 Gilead Sciences Inc Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (he) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN118286245A (zh) 2014-12-26 2024-07-05 埃莫里大学 N4-羟基胞苷和衍生物及与其相关的抗病毒用途
CN110790773A (zh) 2015-04-02 2020-02-14 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
CA2948021C (en) 2015-11-09 2024-06-18 Gilead Sciences, Inc. Pharmaceutical formulations of (2r,5s,13 ar)-8hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzy1)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1'2':4,5]pyrazino [2,1-b][1,3] oxazepine-10-carboxamide
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541515B2 (en) * 2000-08-09 2003-04-01 Merck & Co., Inc. HIV integrase inhibitors
WO2004067531A1 (en) * 2003-01-27 2004-08-12 Pfizer Inc. Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
WO2004101512A2 (en) * 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
EP1564210A1 (en) * 2002-11-20 2005-08-17 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2005112930A1 (en) * 2004-05-21 2005-12-01 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
WO2005113508A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Stable crystal of 4-oxoquinoline compound

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
DE674513T1 (de) * 1992-12-29 1996-01-18 Abbott Lab Inhibitoren der retroviralen protease.
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
ES2324549T5 (es) * 1999-06-04 2012-10-31 Abbott Laboratories Solución farmacéutica que comprende ritonavir, un disolvente (ácido graso de cadena larga) y agua
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
AU2003301439A1 (en) * 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
JP3567162B1 (ja) * 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
US8119602B2 (en) * 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
CA2661943C (en) * 2006-09-12 2015-11-03 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
JP5547067B2 (ja) * 2007-06-29 2014-07-09 ギリアード サイエンシーズ， インコーポレイテッド 治療組成物およびその使用
EP2167088A1 (en) * 2007-06-29 2010-03-31 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541515B2 (en) * 2000-08-09 2003-04-01 Merck & Co., Inc. HIV integrase inhibitors
EP1564210A1 (en) * 2002-11-20 2005-08-17 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
WO2004067531A1 (en) * 2003-01-27 2004-08-12 Pfizer Inc. Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
WO2004101512A2 (en) * 2003-05-13 2004-11-25 Smithkline Beecham Corporation Naphthyridine integrase inhibitors
WO2005113508A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Stable crystal of 4-oxoquinoline compound
WO2005112930A1 (en) * 2004-05-21 2005-12-01 Japan Tobacco Inc. Combinations comprising a 4-isoquinolone derivative and anti-hiv agents

Also Published As

Publication number Publication date
AU2006332664A1 (en) 2007-07-12
NO20083333L (no) 2008-09-29
WO2007079260A9 (en) 2007-08-30
EP1976517A1 (en) 2008-10-08
HRP20080313A2 (en) 2008-11-30
CA2847871C (en) 2016-07-26
JP4676536B2 (ja) 2011-04-27
CA2635468C (en) 2016-08-09
IL192208A (he) 2013-10-31
KR101524165B1 (ko) 2015-06-01
CA2635468A1 (en) 2007-07-12
CA2847871A1 (en) 2007-07-12
WO2007079260A1 (en) 2007-07-12
SG170796A1 (en) 2011-05-30
KR20080081358A (ko) 2008-09-09
US20070219243A1 (en) 2007-09-20
BRPI0620865A2 (pt) 2011-11-29
IL192208A0 (en) 2009-02-11
AU2006332664B2 (en) 2013-03-14
EA201201496A1 (ru) 2013-07-30
NZ569576A (en) 2011-09-30
EP2308490A1 (en) 2011-04-13
CN104069108A (zh) 2014-10-01
KR20140082858A (ko) 2014-07-02
JP2009525265A (ja) 2009-07-09
EA200801619A1 (ru) 2008-10-30
AP2008004522A0 (en) 2008-06-30
EA018544B1 (ru) 2013-08-30
KR20160074018A (ko) 2016-06-27
SG170795A1 (en) 2011-05-30

Similar Documents

Publication Publication Date Title
IL192208A0 (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
PL1948666T3 (pl) Inhibitory integrazy HIV
EP1756069A4 (en) HIV INTEGRASE INHIBITORS
IL177189A0 (en) Hiv integrase inhibitors
AP2870A (en) Odcase inhibitors for the treatment of malaria
IL177858A0 (en) Hiv integrase inhibitors
TWI366567B (en) Bicyclic heterocycles as hiv integrase inhibitors
IL179161A0 (en) Hiv integrase inhibitors: cyclic pyrimidinone compounds
ZA200704130B (en) Protassium salt of an HIV integrase inhibitor
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
IL192242A0 (en) Improved process for the preparation of the salts of 4-(benzimidazolylmethylamino)-benzamides
EP1753767A4 (en) BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
EP1749008A4 (en) BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS
ZA200710389B (en) Process for the copolymerization of propylene
IL183850A0 (en) Hiv protease inhibitors
EP1910363A4 (en) INHIBITORS OF HIV INTEGRASE
IL189939A0 (en) Inhibitors of the hiv integrase enzyme
ZA200806222B (en) Methods for improving the pharmacokinetics of HIV integrase inhibitors
EP1910356A4 (en) HIV integrase
EP1909578A4 (en) INHIBITORS OF HIV INTEGRASE
EP1910355A4 (en) HIV integrase
HK1123735A (en) Methods for improving the pharmacokinetics of hiv integrase inhibitors
PL1928883T3 (pl) Sposób otrzymywania chlorowodorku irynotekanu
ZA200606956B (en) HIV integrase inhibitors